Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2013

01-08-2013 | Original Article

Distress screening remains important during follow-up after primary breast cancer treatment

Authors: Floortje K. Ploos van Amstel, Sanne W. van den Berg, Hanneke W. M. van Laarhoven, Marieke F. M. Gielissen, Judith B. Prins, Petronella B. Ottevanger

Published in: Supportive Care in Cancer | Issue 8/2013

Login to get access

Abstract

Background

To improve psychosocial care, the National Comprehensive Cancer Network recommends the use of the Distress Thermometer (DT) to detect distress among cancer patients.

Objectives

The objectives of this study were to describe the prevalence of distress in breast cancer survivors (BCSs) and to investigate demographic, treatment, and psychosocial variables associated with distress and problems most often reported on the problem list. Moreover, we assessed how many BCSs requested referral to a professional for additional support.

Methods

In a cross-sectional study, 258 BCSs identified at an outpatient clinic of a university hospital were asked to complete the following questionnaires: DT, Quality of Life Questionnaire, Hospital Anxiety and Depression Scale, and Illness Cognition Questionnaire.

Results

Of the 258 identified BCSs, 129 (50 %) completed all questionnaires. After a mean follow-up period of 5.6 (SD, 10) years, 47 (36 %) of these 129 BCSs experienced distress as assessed by the DT. BCSs experienced significantly more distress in the first 2 years than in the period between 2 and 5 years after surgery. Also, more distress was experienced in BCSs treated with surgery, radiotherapy, and chemotherapy compared to those treated with surgery only. Problems most frequently encountered were fatigue (57 %), decrease in muscle strength (47 %), and lack of physical fitness (42 %). Thirty one (69 %) of the distressed BCSs requested or considered referral to a professional. Regression analysis showed that reduced quality of life, reduced cognitive function, and fatigue were predictors of distress.

Conclusion

The current study found that more than one third of all BCSs experienced distress. Screening remains an important part of BCSs' care. The professional should be aware of the potential problems and distress patients may experience.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRef
2.
Dutch Cancer Society (2011) Cancer in the Netherlands until 2020. Dutch Cancer Society, Amsterdam
3.
Montazeri A (2008) Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 27:32PubMedCrossRef
4.
Peuckmann V, Ekholm O, Rasmussen NK et al (2009) Chronic pain and other sequelae in long-term breast cancer survivors: nationwide survey in Denmark. Eur J Pain 13(5):478–485PubMedCrossRef
5.
Servaes P, Verhagen S, Bleijenberg G (2002) Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 13(4):589–598PubMedCrossRef
6.
Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. Natl Cancer Inst 2 94(1):39–49CrossRef
7.
Costanzo ES, Lutgendorf SK, Mattes ML et al (2007) Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br J Cancer 97(12):1625–1631PubMedCrossRef
8.
Garofalo JP, Choppala S, Hamann HA, Gjerde J (2009) Uncertainty during the transition from cancer patient to survivor. Cancer Nurs 32(4):E8–E14PubMedCrossRef
9.
Stanton AL (2012) What happens now? Psychosocial care for cancer survivors after medical treatment completion. J Clin Oncol 30(11):1215–1220PubMedCrossRef
10.
Lavigne JE, Griggs JJ, Tu XM, Lerner DJ (2008) Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. J Cancer Surviv 2(4):296–302PubMedCrossRef
11.
Hansen JA, Feuerstein M, Calvio LC, Olsen CH (2008) Breast cancer survivors at work. J Occup Environ Med 50(7):777–784PubMedCrossRef
12.
National Comprehensive Cancer Network (2011) NCCN clinical practice guidelines in oncology: distress management. US.
13.
Lazarus R, Folkman S (1984) Stress, appraisal, and coping. Springer, New York
14.
Vitek L, Rosenzweig MQ, Stollings S (2007) Distress in patients with cancer: definition, assessment, and suggested interventions. Clin J Oncol Nurs 11(3):413–418PubMedCrossRef
15.
Ryan H, Schofield P, Cockburn J et al (2005) How to recognize and manage psychological distress in cancer patients. Eur J Cancer Care 14(1):7–15CrossRef
16.
Falagas M, Zarkadoulia E, Ioannidou E, Peppas G, Christodoulou C, Rafailidis P (2007) The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Research 9:4CrossRef
17.
Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330(7493):702PubMedCrossRef
18.
Evers AWM, Kraaimaat FW, van Lankveld W, Jongen PJH, Jacobs JWG, Bijlsma JWJ (2001) Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol 69:1026–1036PubMedCrossRef
19.
Stanton AL, Ganz PA, Rowland JH, Meyerowitz BE, Krupnick JL, Sears SR (2005) Promoting adjustment after treatment for cancer. Cancer 104(11):2608–2613PubMedCrossRef
20.
Holland JC, Reznik I (2005) Pathways for psychosocial care of cancer survivors. Cancer suppl 104(11)
21.
Henselmans I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV (2010) Identification and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health Psychol 29(2):160–168PubMedCrossRef
22.
Helgeson VS, Snyder P, Seltman H (2004) Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change. Health Psychol 2004 23(1):3–15
23.
Hinnen C, Ranchor AV, Sanderman R, Snijders TAB, Hagedoorn M, Coyne JC (2008) Course of distress in breast cancer patients, their partners, and matched control couples. Ann Behav Med 36(2):141–148PubMedCrossRef
24.
Bauwens S, Baillon C, Distelmans W, Theuns P (2009) The ‘Distress Barometer’: validation of method of combining the distress thermometer with a rated complaint scale. Psycho-Oncology 18(5):534–542PubMedCrossRef
25.
Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE (2008) Screening and referral for psychosocial distress in oncologic practice: use of the distress thermometer. Cancer 113(4):870–878PubMedCrossRef
26.
Gessler S, Low J, Daniells E, Williams R, Brough V, Tookman A, Jones L (2008) Screening for distress in cancer patients: is the distress thermometer a valid measure in the UK and does it measure change over time? A prospective validation study. Psycho-Oncology 17(6):538–547PubMedCrossRef
27.
Ransom S, Jacobsen PB, Booth-Jones M (2006) Validation of the distress thermometer with bone marrow transplant patients. Psycho-Oncology 15(7):604–612PubMedCrossRef
28.
Jacobsen PB, Donovan KA, Trask PC et al (2005) Screening for psychologic distress in ambulatory cancer patients. Cancer 103(7):1494–1502PubMedCrossRef
29.
Hoffman BM, Zevon MA, D'Arrigo MC, Cecchini TB (2004) Screening for distress in cancer patients: the NCCN rapid-screening measure. Psycho-Oncology 13(11):792–799PubMedCrossRef
30.
Gil F, Grassi L, Travado L, Tomamichel M, Gonzalez JR (2005) Use of distress and depression thermometers to measure psychosocial morbidity among southern European cancer patients. Support Care Cancer 13(8):600–606PubMedCrossRef
31.
Dutch Association of Comprehensive Cancer Centers (2010) Guideline: detection of need for psychosocial care, the Netherlands.
32.
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370PubMedCrossRef
33.
Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 52(2):69–77PubMedCrossRef
34.
Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM (1997) A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27(2):363–370PubMedCrossRef
35.
Aaronson N, Ahmedzai A, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30. Journal Natl Cancer Inst 85(5):365–376CrossRef
36.
Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A (1997) Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 6(2):103–108PubMedCrossRef
37.
Sprangers MA, Groenvold M, Arraras JI et al (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14(10):2756–2768PubMed
38.
Greimel E, Bottomley A, Cull A et al (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39(10):1402–1408PubMedCrossRef
39.
Evers A, Kraaimaat F, Wv L, Jacobs W, Bijlsma J (1998) De ziekte-cognitie-lijst (ZCL). Gedragstherapie 31:205–220
40.
41.
Phipps AI, Ichikawa L, Bowles EJ et al (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60–66PubMedCrossRef
42.
Tabuchnink BG, Fidell LS (2007) Using multivariate analysis, 5th edn. Pearson Education, Boston
43.
Bower JE, Ganz PA, Desmond KA et al (2006) Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106(4):751–758PubMedCrossRef
44.
Norton S, Cosco T, Doyle F, Done J,Sacker A (2013) The hospital anxiety and depression scale: a meta confirmatory factor analysis. J Psychosom Res 74(1):74–81
Metadata
Title
Distress screening remains important during follow-up after primary breast cancer treatment
Authors
Floortje K. Ploos van Amstel
Sanne W. van den Berg
Hanneke W. M. van Laarhoven
Marieke F. M. Gielissen
Judith B. Prins
Petronella B. Ottevanger
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1764-0

Other articles of this Issue 8/2013

Supportive Care in Cancer 8/2013 Go to the issue

Review Article

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

Original Article

The impact of clinical and sociodemographic features on quality of life in patients with early stage cancers using the Functional Assessment of Cancer Therapy-General assessment tool

Original Article

Longitudinal quality of life in Turkish patients with head and neck cancer undergoing radiotherapy

Original Article

Dosimetric and clinical impact of 3D vs. 2D planning in palliative radiotherapy for bone metastases

Original Article

Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia

Original Article

Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits